FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,048,269 | -79.7% | 494,466 | -54.4% | 0.00% | -100.0% |
| Q2 2023 | $5,163,805 | -31.8% | 1,084,833 | -18.4% | 0.00% | -50.0% |
| Q1 2023 | $7,573,367 | -7.3% | 1,328,661 | +64.0% | 0.00% | 0.0% |
| Q4 2022 | $8,173,263 | -65.0% | 810,036 | -22.2% | 0.00% | -60.0% |
| Q3 2022 | $23,345,000 | -13.1% | 1,041,727 | -4.0% | 0.01% | -16.7% |
| Q2 2022 | $26,879,000 | +206.1% | 1,084,670 | +378.9% | 0.01% | +200.0% |
| Q1 2022 | $8,781,000 | -63.1% | 226,477 | -44.4% | 0.00% | -60.0% |
| Q4 2021 | $23,824,000 | -29.6% | 407,171 | -28.7% | 0.01% | -28.6% |
| Q3 2021 | $33,839,000 | -34.3% | 570,923 | -3.8% | 0.01% | -41.7% |
| Q2 2021 | $51,504,000 | -23.8% | 593,442 | -27.6% | 0.01% | -29.4% |
| Q1 2021 | $67,571,000 | -4.2% | 819,542 | +5.7% | 0.02% | -5.6% |
| Q4 2020 | $70,509,000 | +34.8% | 775,414 | -40.8% | 0.02% | +20.0% |
| Q3 2020 | $52,319,000 | +46.2% | 1,308,967 | +25.5% | 0.02% | +36.4% |
| Q2 2020 | $35,792,000 | +116.5% | 1,043,196 | +40.1% | 0.01% | +83.3% |
| Q1 2020 | $16,534,000 | +25.1% | 744,469 | +10.2% | 0.01% | +100.0% |
| Q4 2019 | $13,219,000 | +86.4% | 675,437 | +47.9% | 0.00% | +50.0% |
| Q3 2019 | $7,090,000 | -21.4% | 456,587 | +2.8% | 0.00% | -33.3% |
| Q2 2019 | $9,015,000 | +35.4% | 444,116 | +17.2% | 0.00% | +50.0% |
| Q1 2019 | $6,656,000 | +50.4% | 378,850 | +9.8% | 0.00% | +100.0% |
| Q4 2018 | $4,426,000 | +172.7% | 344,958 | +246.1% | 0.00% | – |
| Q3 2018 | $1,623,000 | +423.5% | 99,677 | +265.1% | 0.00% | – |
| Q2 2018 | $310,000 | -0.3% | 27,298 | -46.4% | 0.00% | – |
| Q4 2017 | $311,000 | -37.8% | 50,966 | -59.6% | 0.00% | – |
| Q3 2017 | $500,000 | +38.1% | 126,226 | +12.9% | 0.00% | – |
| Q2 2017 | $362,000 | -44.7% | 111,775 | -22.4% | 0.00% | – |
| Q1 2017 | $655,000 | +956.5% | 144,053 | +479.6% | 0.00% | – |
| Q4 2016 | $62,000 | -44.1% | 24,853 | -29.8% | 0.00% | – |
| Q3 2016 | $111,000 | +82.0% | 35,417 | -1.5% | 0.00% | – |
| Q2 2016 | $61,000 | -80.5% | 35,966 | -79.3% | 0.00% | – |
| Q1 2016 | $313,000 | +247.8% | 173,924 | +551.6% | 0.00% | – |
| Q4 2015 | $90,000 | +13.9% | 26,691 | +80.4% | 0.00% | – |
| Q3 2015 | $79,000 | 0.0% | 14,797 | +20.8% | 0.00% | – |
| Q2 2015 | $79,000 | -56.4% | 12,250 | -66.9% | 0.00% | – |
| Q1 2015 | $181,000 | -50.9% | 37,013 | -49.6% | 0.00% | – |
| Q4 2014 | $369,000 | -13.6% | 73,436 | -12.3% | 0.00% | – |
| Q3 2014 | $427,000 | -0.2% | 83,692 | +23.3% | 0.00% | – |
| Q2 2014 | $428,000 | +67.2% | 67,877 | +158.0% | 0.00% | – |
| Q1 2014 | $256,000 | -0.4% | 26,310 | -35.8% | 0.00% | – |
| Q4 2013 | $257,000 | – | 40,991 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |